Sabby Management Sends Letter to the Board of Directors of Strata Skin
January 02, 2018 at 09:40 pm
Share
On January 2, 2018, Sabby Management, LLC sent to the Board of Directors of Strata Skin Sciences, Inc. a letter expressing dissatisfaction with recent actions taken by the Company’s Board of Directors. In the letter, Sabby Management stated that in its opinion, the Company has rejected its best path forward without proposing another clear alternative. In addition, Sabby Management stated that it would like the board to provide an update by January 22, 2018 on its exploration of its strategic alternatives. At such time, whether or not it receives an update from the Company, it may reevaluate its investment and may consider taking action, including calling on all shareholders to vote for alternative leadership at the board level at the next shareholder’s meeting. Further, Sabby Management stated that change in the leadership at the board level may be necessary.
STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Companyâs products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
STRATA SKIN SCIENCES, INC. 
